STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial

Despite recent important progresses in the diagnosis and treatment of lung cancers, it remains a leading cause of cancer death worldwide [1]. The development of targeted therapies and immune checkpoints inhibitors has significantly improved PFS and OS for patients with advanced diseases. Therapeutic options for metastatic NSCLC depend on the detection of somatic oncogenic drivers or on the level of PD-L1 expression. Tumors harboring sensitizing EGFR, BRAF, KRAS p.G12C or MET activating mutations (mut) may benefit from targeted therapy such as EGFR tyrosine kinase inhibitors (TKI), BRAF/MEK inhibitors, KRAS or MET inhibitors.

Source: Lung Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Jean Baptiste Oudart, Simon Garinet, Caroline Leger, Fabrice Barlesi, Julien Mazi ères, Gaelle Jeannin, Clarisse Audigier-Valette, Denis Morot-Sibilot, Alexandra Langlais, Elodie Amour, Nathalie Mathiot, Gary Birsen, Hélène Blons, Marie Wislez Source Type: research